고양이 백신 시장 규모, 점유율, 동향 분석 보고서 : 백신 유형별, 질병 유형별, 투여 경로별, 면역 기간별, 성분별, 지역별, 부문별 예측(2024-2030년)

Cat Vaccine Market Growth & Trends:

The global cat vaccine market size is expected to reach USD 2.5 billion by 2030 and is anticipated to expand at a CAGR of 9.4% from 2024 to 2030, according to a new report by Grand View Research, Inc.Rising pet ownership, emerging diseases in cats, and rising disposable income is expected to increase the market value for cat vaccines. Furthermore, pharmaceutical industry investments are also expected to boost market growth.

The rising market trend is due to the growing awareness among pet owners about the necessity of cat vaccines, promoting preventive healthcare, and ensuring the well-being of their feline companions. Pet owners now prioritize products that match their pets' dietary needs and personal values, turning to online pet brands for convenient access to premium and nutritious pet items.

Cat Vaccine Market Report Highlights:

• Based on vaccine type, the modified/attenuated live segment dominated the market with the largest revenue share of 50.1% in 2023. The demonstrated efficacy of modified/attenuated live vaccines against feline panleukopenia and herpesvirus, has boosted confidence in both pet owners and veterinarians.
• Based on disease type, the feline respiratory diseases (FRDs) segment held the largest share of 32.4% in 2023 owing to the increasing prevalence of FRDs, eventually driving market growth.
• The feline leukemia segment is anticipated to witness the fastest CAGR of 9.8% over the forecast period.
• Based on route of administration, the injectables segment held the largest market share, with 77.4% in 2023. Continuous research and development in vaccine technology are propelling the injectables segment in the market.
• Based on duration of immunity, the 1-year segment held the largest market share of 50.1% in 2023 and the diligent and evidence-based practices of veterinary organizations such as the American Association of Feline Practitioners (AAFP) guide the development of safe and effective vaccines.
• Based on component, the combined vaccine segment held the largest market share, with 64.0% in 2023, and is expected to grow at the fastest CAGR of 9.5% over the forecast period.
• In 2023, North America dominated the market with a revenue share of 38.1% owing to the strict regulations overseeing animal vaccines and upholding high-quality feline healthcare standards.
• Some of the major companies include Virbac; C.H. Boehringer Sohn AG & Co. KG.; Elanco; Zoetis; Merck & Co.; Bioveta, a.s.; Indian Immunologicals Ltd.; among others.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Vaccine type
  • 1.2.2. Disease type
  • 1.2.3. Route of administration
  • 1.2.4. Duration of immunity
  • 1.2.5. Component
  • 1.2.6. Region
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Vaccine type outlook
  • 2.2.2. Disease type outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Duration of immunity outlook
  • 2.2.5. Component outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cat Vaccines Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising pet ownership
    • 3.2.1.2. Emerging diseases in cats
    • 3.2.1.3. Rising disposable income
    • 3.2.1.4. Pharmaceutical industry investment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent regulatory policies and regulations
    • 3.2.2.2. High cost of Vaccines
• 3.3. Cat Vaccines Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cat Vaccines Market: Vaccine Type Estimates & Trend Analysis

• 4.1. Vaccine Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Cat Vaccines Market by Vaccine Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 4.4.1. Modified/attenuated (live)
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Inactivated (killed)
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cat Vaccines Market: Disease Type Estimates & Trend Analysis

• 5.1. Disease Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Cat Vaccines Market by Disease Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 5.4.1. Feline leukemia
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Feline panleukopenia (Feline distemper)
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Feline respiratory diseases
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Feline rabies
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Other diseases
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Cat Vaccines Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Cat Vaccines Market by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 6.4.1. Injectables
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Intranasal
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Oral
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Cat Vaccines Market: Duration of Immunity Estimates & Trend Analysis

• 7.1. Duration of Immunity Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Cat Vaccines Market by Duration of Immunity Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 7.4.1. 1 Year
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. 3 Years
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Cat Vaccines Market: Component Estimates & Trend Analysis

• 8.1. Component Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Cat Vaccines Market by Component Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 8.4.1. Combined vaccine
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.4.2. Mono vaccine
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Cat Vaccines Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Mexico
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/ reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
• 10.4. Company Profiles
  • 10.4.1. Virbac
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. C.H. Boehringer Sohn AG & Co. KG.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Elanco
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Zoetis
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Merck & Co.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Bioveta, a.s.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Indian Immunologicals Ltd
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives